Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 65

1.

The Synthetic Microneurotrophin BNN27 Affects Retinal Function in Rats With Streptozotocin-Induced Diabetes.

Ibán-Arias R, Lisa S, Mastrodimou N, Kokona D, Koulakis E, Iordanidou P, Kouvarakis A, Fothiadaki M, Papadogkonaki S, Sotiriou A, Katerinopoulos HE, Gravanis A, Charalampopoulos I, Thermos K.

Diabetes. 2018 Feb;67(2):321-333. doi: 10.2337/db17-0391. Epub 2017 Dec 5.

PMID:
29208634
2.

Endogenous and Synthetic Cannabinoids as Therapeutics in Retinal Disease.

Kokona D, Georgiou PC, Kounenidakis M, Kiagiadaki F, Thermos K.

Neural Plast. 2016;2016:8373020. doi: 10.1155/2016/8373020. Epub 2016 Jan 6. Review.

3.

Dendrimers as tunable vectors of drug delivery systems and biomedical and ocular applications.

Kalomiraki M, Thermos K, Chaniotakis NA.

Int J Nanomedicine. 2015 Dec 22;11:1-12. doi: 10.2147/IJN.S93069. eCollection 2016. Review.

4.

Trans-Modulation of the Somatostatin Type 2A Receptor Trafficking by Insulin-Regulated Aminopeptidase Decreases Limbic Seizures.

De Bundel D, Fafouri A, Csaba Z, Loyens E, Lebon S, El Ghouzzi V, Peineau S, Vodjdani G, Kiagiadaki F, Aourz N, Coppens J, Walrave L, Portelli J, Vanderheyden P, Chai SY, Thermos K, Bernard V, Collingridge G, Auvin S, Gressens P, Smolders I, Dournaud P.

J Neurosci. 2015 Aug 26;35(34):11960-75. doi: 10.1523/JNEUROSCI.0476-15.2015.

5.
6.

Effects of octreotide and insulin on colon cancer cellular proliferation and correlation with hTERT activity.

Ayiomamitis GD, Notas G, Zaravinos A, Drygiannakis I, Georgiadou M, Sfakianaki O, Mastrodimou N, Thermos K, Kouroumalis E.

Oncoscience. 2014 Jun 30;1(6):457-67. eCollection 2014.

7.

Effects of novel synthetic microneurotrophins in diabetic retinopathy.

Lisa S, Iban-Arias R, Kokona D, Charalampopoulos I, Gravanis A, Thermos K.

Springerplus. 2015 Jun 12;4(Suppl 1):L25. doi: 10.1186/2193-1801-4-S1-L25. eCollection 2015. No abstract available.

8.

Neurosteroids and microneurotrophins signal through NGF receptors to induce prosurvival signaling in neuronal cells.

Gravanis A, Calogeropoulou T, Panoutsakopoulou V, Thermos K, Neophytou C, Charalampopoulos I.

Sci Signal. 2012 Oct 16;5(246):pt8. doi: 10.1126/scisignal.2003387.

PMID:
23074265
9.

Pasireotide (SOM230) protects the retina in animal models of ischemia induced retinopathies.

Kokona D, Mastrodimou N, Pediaditakis I, Charalampopoulos I, Schmid HA, Thermos K.

Exp Eye Res. 2012 Oct;103:90-8. doi: 10.1016/j.exer.2012.08.005. Epub 2012 Sep 1.

PMID:
22960304
10.

The neurosteroid dehydroepiandrosterone (DHEA) protects the retina from AMPA-induced excitotoxicity: NGF TrkA receptor involvement.

Kokona D, Charalampopoulos I, Pediaditakis I, Gravanis A, Thermos K.

Neuropharmacology. 2012 Apr;62(5-6):2106-17. doi: 10.1016/j.neuropharm.2012.01.006. Epub 2012 Jan 17.

PMID:
22269901
11.

Somatostatin receptor activation (sst(1) -sst(5) ) differentially influences human retinal pigment epithelium cell viability.

Papadaki T, Tsilimbaris M, Pallikaris I, Thermos K.

Acta Ophthalmol. 2010 Sep;88(6):e228-33. doi: 10.1111/j.1755-3768.2010.01945.x.

12.

Hippocampal sst(1) receptors are autoreceptors and do not affect seizures in rats.

De Bundel D, Aourz N, Kiagiadaki F, Clinckers R, Hoyer D, Kastellakis A, Michotte Y, Thermos K, Smolders I.

Neuroreport. 2010 Mar 10;21(4):254-8. doi: 10.1097/WNR.0b013e3283353a64.

PMID:
20134357
13.

Activation of somatostatin receptor (sst 5) protects the rat retina from AMPA-induced neurotoxicity.

Kiagiadaki F, Savvaki M, Thermos K.

Neuropharmacology. 2010 Jan;58(1):297-303. doi: 10.1016/j.neuropharm.2009.06.028. Epub 2009 Jul 2.

PMID:
19576912
14.

GABA antagonists reverse the somatostatin dependent attenuation of rat locomotor activity.

Marazioti A, Spyraki C, Thermos K.

Neuropeptides. 2009 Jun;43(3):207-12. doi: 10.1016/j.npep.2009.04.001. Epub 2009 May 2.

PMID:
19414189
15.

Somatostatin analogues as therapeutics in retinal disease.

Vasilaki A, Thermos K.

Pharmacol Ther. 2009 Jun;122(3):324-33. doi: 10.1016/j.pharmthera.2009.03.010. Epub 2009 Apr 5. Review.

PMID:
19351548
16.

Antidepressants influence somatostatin levels and receptor pharmacology in brain.

Pallis E, Vasilaki A, Fehlmann D, Kastellakis A, Hoyer D, Spyraki C, Thermos K.

Neuropsychopharmacology. 2009 Mar;34(4):952-63. doi: 10.1038/npp.2008.133. Epub 2008 Sep 17.

17.

Activation of somatostatin receptors in the globus pallidus increases rat locomotor activity and dopamine release in the striatum.

Marazioti A, Pitychoutis PM, Papadopoulou-Daifoti Z, Spyraki C, Thermos K.

Psychopharmacology (Berl). 2008 Dec;201(3):413-22. doi: 10.1007/s00213-008-1305-6. Epub 2008 Sep 3.

PMID:
18766330
18.

Somatostatin increases rat locomotor activity by activating sst(2) and sst (4) receptors in the striatum and via glutamatergic involvement.

Santis S, Kastellakis A, Kotzamani D, Pitarokoili K, Kokona D, Thermos K.

Naunyn Schmiedebergs Arch Pharmacol. 2009 Feb;379(2):181-9. doi: 10.1007/s00210-008-0346-z. Epub 2008 Sep 3.

PMID:
18766327
19.

Effect of intravitreal administration of somatostatin and sst2 analogs on AMPA-induced neurotoxicity in rat retina.

Kiagiadaki F, Thermos K.

Invest Ophthalmol Vis Sci. 2008 Jul;49(7):3080-9. doi: 10.1167/iovs.07-1644. Epub 2008 Apr 4.

PMID:
18390640
20.

Novel signals mediating the functions of somatostatin: the emerging role of NO/cGMP.

Thermos K.

Mol Cell Endocrinol. 2008 May 14;286(1-2):49-57. doi: 10.1016/j.mce.2008.02.008. Epub 2008 Feb 17. Review.

PMID:
18384933
21.

The role of nitric oxide and cGMP in somatostatin's protection against retinal ischemia.

Mastrodimou N, Kiagiadaki F, Thermos K.

Invest Ophthalmol Vis Sci. 2008 Jan;49(1):342-9. doi: 10.1167/iovs.07-0341.

PMID:
18172111
22.

Dopamine (D1) receptor activation and nitrinergic agents influence somatostatin levels in rat retina.

Kiagiadaki F, Koulakis E, Thermos K.

Exp Eye Res. 2008 Jan;86(1):18-24. Epub 2007 Sep 14.

PMID:
17961553
23.

Modification of inherent and drug-induced dopaminergic activity after exposure to benzo(alpha)pyrene.

Konstandi M, Harkitis P, Thermos K, Ogren SO, Johnson EO, Tzimas P, Marselos M.

Neurotoxicology. 2007 Jul;28(4):860-7. Epub 2007 May 6. Erratum in: Neurotoxicology. 2007 Nov;28(6):1275.

PMID:
17570529
24.

RT-PCR and immunocytochemistry studies support the presence of somatostatin, cortistatin and somatostatin receptor subtypes in rat Kupffer cells.

Xidakis C, Mastrodimou N, Notas G, Renieri E, Kolios G, Kouroumalis E, Thermos K.

Regul Pept. 2007 Oct 4;143(1-3):76-82. Epub 2007 Mar 30.

PMID:
17481746
25.

The inhibitory effect of opioids on HepG2 cells is mediated via interaction with somatostatin receptors.

Notas G, Kampa M, Nifli AP, Xidakis K, Papasava D, Thermos K, Kouroumalis E, Castanas E.

Eur J Pharmacol. 2007 Jan 19;555(1):1-7. Epub 2006 Oct 18.

PMID:
17113072
26.

Somatostatin receptors in wildtype and somatostatin deficient mice and their involvement in nitric oxide physiology in the retina.

Mastrodimou N, Vasilaki A, Papadioti A, Low MJ, Hoyer D, Thermos K.

Neuropeptides. 2006 Oct;40(5):365-73. Epub 2006 Sep 28.

PMID:
17010429
27.

Chronic antidepressant treatment modulates the release of somatostatin in the rat nucleus accumbens.

Pallis EG, Spyraki C, Thermos K.

Neurosci Lett. 2006 Feb 27;395(1):76-81. Epub 2005 Nov 15.

PMID:
16293366
28.

Somatostatin receptors (sst2) regulate cGMP production in rat retina.

Mastrodimou N, Kiagiadaki F, Hodjarova M, Karagianni E, Thermos K.

Regul Pept. 2006 Jan 15;133(1-3):41-6. Epub 2005 Nov 8.

PMID:
16280179
29.

The somatostatin sst1 receptor: an autoreceptor for somatostatin in brain and retina?

Thermos K, Bagnoli P, Epelbaum J, Hoyer D.

Pharmacol Ther. 2006 Jun;110(3):455-64. Epub 2005 Nov 7. Review.

PMID:
16274747
30.

Somatostatin modulates dopamine release in rat retina.

Kouvidi E, Papadopoulou-Daifoti Z, Thermos K.

Neurosci Lett. 2006 Jan 2;391(3):82-6.

PMID:
16183196
31.

Behavioral pharmacological properties of a novel cannabinoid 1',1'-dithiolane delta8-THC analog, AMG-3.

Antoniou K, Galanopoulos A, Vlachou S, Kourouli T, Nahmias V, Thermos K, Panagis G, Daifoti Z, Marselos M, Papahatjis D, Spyraki C.

Behav Pharmacol. 2005 Sep;16(5-6):499-510.

PMID:
16148456
32.

Somatostatin receptors in the ventral pallidum/substantia innominata modulate rat locomotor activity.

Marazioti A, Kastellakis A, Antoniou K, Papasava D, Thermos K.

Psychopharmacology (Berl). 2005 Sep;181(2):319-26. Epub 2005 Oct 14.

PMID:
15778878
33.

Effect of somatostatin analogues on chemically induced ischaemia in the rat retina.

Mastrodimou N, Lambrou GN, Thermos K.

Naunyn Schmiedebergs Arch Pharmacol. 2005 Jan;371(1):44-53. Epub 2005 Jan 12.

PMID:
15645293
34.

The somatostatin receptor (sst1) modulates the release of somatostatin in the nucleus accumbens of the rat.

Vasilaki A, Papasava D, Hoyer D, Thermos K.

Neuropharmacology. 2004 Sep;47(4):612-8.

PMID:
15380378
35.

Effect of somatostatin on nitric oxide production in human retinal pigment epithelium cell cultures.

Vasilaki A, Papadaki T, Notas G, Kolios G, Mastrodimou N, Hoyer D, Tsilimbaris M, Kouroumalis E, Pallikaris I, Thermos K.

Invest Ophthalmol Vis Sci. 2004 May;45(5):1499-506.

PMID:
15111608
36.

Cortistatin production by HepG2 human hepatocellular carcinoma cell line and distribution of somatostatin receptors.

Notas G, Kolios G, Mastrodimou N, Kampa M, Vasilaki A, Xidakis C, Castanas E, Thermos K, Kouroumalis E.

J Hepatol. 2004 May;40(5):792-8.

PMID:
15094227
37.

The somatostatin receptor (sst1) modulates the release of somatostatin in rat retina.

Mastrodimou N, Thermos K.

Neurosci Lett. 2004 Feb 6;356(1):13-6.

PMID:
14746890
38.

The role of lanreotide in the treatment of choroidal neovascularization secondary to age-related macular degeneration: a pilot clinical trial.

Papadaki T, Tsilimbaris M, Thermos K, Karavellas M, Samonakis D, Papapdakis A, Linardakis M, Kouromalis E, Pallikaris I.

Retina. 2003 Dec;23(6):800-7.

PMID:
14707831
39.

Functional mapping of somatostatin receptors in the retina: a review.

Thermos K.

Vision Res. 2003 Aug;43(17):1805-15. Review.

40.

Somatostatin receptors (sst2) are coupled to Go and modulate GTPase activity in the rabbit retina.

Vasilaki A, Georgoussi Z, Thermos K.

J Neurochem. 2003 Feb;84(4):625-32.

41.

Somatostatin receptor immunoreactivity in the eye of the adult newt (Pleurodeles waltlii Michan).

Grigoryan EN, Vasilaki A, Mastrodimou N, Thermos K.

Neurosci Lett. 2003 Feb 13;337(3):143-6.

PMID:
12536044
42.

Somatostatin mediates nitric oxide production by activating sst(2) receptors in the rat retina.

Vasilaki A, Mouratidou M, Schulz S, Thermos K.

Neuropharmacology. 2002 Oct;43(5):899-909.

PMID:
12384175
43.
44.

NADPH-diaphorase colocalization with somatostatin receptor subtypes sst2A and sst2B in the retina.

Vasilaki A, Gardette R, Epelbaum J, Thermos K.

Invest Ophthalmol Vis Sci. 2001 Jun;42(7):1600-9.

PMID:
11381067
45.

Cis- and trans-N-benzyl-octahydrobenzo[g]quinolines. Adrenergic and dopaminergic activity studies.

Thermos K, Froudakis GE, Tagmatarchis N, Katerinopoulos HE.

Bioorg Med Chem Lett. 2001 Apr 9;11(7):883-6.

PMID:
11294383
46.
47.

N-(Iodopropenyl)-octahydrobenzo[f]- and -[g]quinolines: synthesis and adrenergic and dopaminergic activity studies.

Tagmatarchis N, Thermos K, Katerinopoulos HE.

J Med Chem. 1998 Oct 8;41(21):4165-70.

PMID:
9767652
48.

Anaphylactic shock after a single oral intake of acetazolamide.

Tzanakis N, Metzidaki G, Thermos K, Spyraki CH, Bouros D.

Br J Ophthalmol. 1998 May;82(5):588. No abstract available.

49.

Treatment of hepatocellular carcinoma with octreotide: a randomised controlled study.

Kouroumalis E, Skordilis P, Thermos K, Vasilaki A, Moschandrea J, Manousos ON.

Gut. 1998 Mar;42(3):442-7.

50.

Dopamine-somatostatin interactions in the rat striatum: an in vivo microdialysis study.

Thermos K, Radke J, Kastellakis A, Anagnostakis Y, Spyraki C.

Synapse. 1996 Mar;22(3):209-16.

PMID:
9132988

Supplemental Content

Loading ...
Support Center